Immunovant
IMVT
132 hedge funds and large institutions have $980M invested in Immunovant in 2022 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 52 increasing their positions, 28 reducing their positions, and 18 closing their positions.
3,504% more call options, than puts
Call options by funds: $8.87M | Put options by funds: $246K
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
312% more capital invested
Capital invested by funds: $238M → $980M (+$742M)
117% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 18
86% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 28
18% more funds holding
Funds holding: 112 → 132 (+20)
6.16% more ownership
Funds ownership: 36.59% → 42.75% (+6.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$39.7M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$32.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$28.1M |
| 5 |
CAC
Cowen and Company
New York
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AGM
Alpine Global Management
New York
|
-$35.9M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$21.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.3M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$11.9M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$3.23M |
IMVT Hedge Fund Activity: Q4 2022 in Review
132 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q4 2022, worth a combined $980M — up 312% from $238M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new IMVT positions and 18 closed out — a net gain of 21 holders — while 52 added to existing stakes and 28 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $39.7M. The largest seller was Alpine Global Management, cutting an estimated $35.9M.
- 132 institutional investors held Immunovant (IMVT) as of Q4 2022, up from 112 in Q3 2022.
- Funds reported $980M of Immunovant stock for Q4 2022, up 312% quarter-over-quarter.
- 39 funds opened new Immunovant positions in Q4 2022 and 18 closed out, a net change of +21 holders.
- The largest Immunovant buyer in Q4 2022 was Logos Global Management, an estimated $39.7M added.
- The largest Immunovant seller in Q4 2022 was Alpine Global Management, an estimated $35.9M sold.
Based on aggregated 13F filings for Q4 2022.